Communication from the GPhC regarding Regulatory Concerns
Communication from the GPhC regarding Regulatory Concerns Regarding the Supply and Promotion of Weight-Management Medicines – Mounjaro®, Wegovy® and Related GLP-1 Therapies
Emerging issues – Communique from the GPhC
As part of maintaining professional vigilance and regulatory compliance across pharmacy services, PCL would like to draw attention to several critical issues recently highlighted by the General Pharmaceutical Council (GPhC).
New MHRA/NICE Collaboration
The UK is entering a new phase of innovation in how it regulates, assesses, and adopts new medicines—and it’s a development the global pharmaceutical and biopharmaceutical industry cannot afford to overlook.
Journalists – Be Careful What You Write About Medicines
The MHRA continue to scrutinise and take action against Pharmacies and Clinics who are promoting Prescription Only Medicines (POMs) to the public. However, this month’s advertising investigations bulletin also includes action against a journalist newspaper article.
Emerging Risks in Pharmacy Practice: Key Updates from the GPhC
In this blog I want to highlight some critical updates from the General Pharmaceutical Council (GPhC) that every pharmacy professional—whether you’re a pharmacist, technician, or pharmacy owner—should be aware of. These issues have prompted serious regulatory concerns and demand thoughtful consideration and action where appropriate.